Resveratrol.

Resveratrol and quercetin are both processed by the same sulfotransferase enzymes, and quercetin is a potent inhibitor of resveratrol sulfation in human liver tissue. Because they compete for that same clearance step, quercetin can slow how fast resveratrol is inactivated, leaving more of the free form available.

Pterostilbene is the dimethylated form of the same stilbene skeleton and resists conjugation far better, so it holds a higher blood level for longer. Combining them gives an early peak plus a slower tail.

Sirtuins strip acetyl groups using NAD as the cosubstrate, consuming one NAD per reaction. Resveratrol nudges the enzyme, and NAD availability sets how much work it can actually do.

NR enters the salvage route and raises the intracellular NAD pool that sirtuins draw on. Pairing a precursor with an activator addresses both the fuel and the signal.

NMN is one step from NAD in the salvage pathway and lifts the same cofactor pool sirtuins consume. Formulas pair it with a stilbene activator for that reason.

Resveratrol is almost entirely glucuronidated and sulfated on first pass, and piperine inhibits those conjugating enzymes. Circulating intact stilbene rises as a result.

Curcumin and resveratrol are both cleared mainly by glucuronidation, so each occupies capacity the other would use and both stay around longer. Their downstream targets in inflammatory signalling also differ.

Ascorbate donates an electron to the stilbene radical left after it quenches an oxidant, returning the polyphenol to its active form. The stilbene pool then works through more cycles.

Urolithin A promotes mitophagy while resveratrol pushes biogenesis signalling through PGC-1alpha. Removal and renewal are the two halves of mitochondrial turnover.

Mitochondria built under PGC-1alpha signalling need an electron carrier to run, and CoQ10 fills that slot in the respiratory chain. One supplies the signal, the other the working part.

Polyphenols including stilbenes bind non-heme iron in the gut lumen into complexes the intestine cannot absorb. Spacing the doses keeps iron uptake intact.

Resveratrol reduces platelet aggregation through cyclooxygenase and thromboxane signalling, the same output marine omega-3 lowers from the substrate side. The two effects on normal clotting add up.

A randomised trial gave delta-tocotrienol alongside resveratrol in adults with clustered metabolic risk markers and reported changes in circulating microRNA expression. That makes this a cited combination rather than an inferred one. MicroRNA levels are regulatory markers, several steps upstream of any clinical endpoint. The pairing has a study behind it; the meaning of the marker change does not follow automatically.

Rather than scavenging radicals at meaningful plasma concentrations, most of what resveratrol does to redox balance runs through Nrf2-driven transcription of the enzymes that make and recycle glutathione. That places the two in one pathway, with resveratrol upstream. Oral glutathione's own absorption is a separate and contested question. The mechanism is well described in cells; the human dose-response is not.

Glutathione synthesis is limited by cysteine availability, and N-acetylcysteine supplies it. Resveratrol acts on the transcription of the enzymes in that same pathway through Nrf2. So one partner raises enzyme expression and the other supplies substrate, which is a coherent pairing on biochemistry alone. Neither part of that argument is a measured clinical outcome.

A substantial share of ingested resveratrol is reduced by colonic bacteria to dihydroresveratrol, and the glucoside polydatin is deglycosylated by bacterial beta-glucosidases before absorption. That means the microbiota partly determine which metabolites a person ends up with. It also means between-person variability in response has a microbial component. Whether adding specific strains shifts that conversion usefully is not established.

Resveratrol is poorly water-soluble, and complexing polyphenols with phosphatidylcholine is a standard way to raise their measured plasma exposure. The endpoint that improves is a pharmacokinetic one, not a clinical one, and rapid conjugation in the gut wall and liver still applies. Higher exposure is worth having but is not itself a benefit. Confidence sits at Promising because the data are formulation-specific.

Lecithin disperses a poorly soluble powder into fine droplets or micelles, which is why it appears in phytosome-style and emulsion formats. For resveratrol the practical measure is dissolution and plasma exposure. Sunflower-derived lecithin is used where a soy-free label is needed. The reasoning is formulation chemistry rather than a physiological pairing.

Dissolving resveratrol into a medium-chain triglyceride carrier avoids the dissolution step that limits a dry powder. Medium-chain triglycerides are hydrolysed quickly and do not need micelle formation to the same extent as long-chain fat. What this changes is the pharmacokinetic profile. It does not alter how much survives first-pass conjugation.

Resveratrol's low free plasma concentration comes almost entirely from fast sulfation and glucuronidation in the gut wall and liver. Catechins are handled by the same enzyme families and can inhibit them, so co-dosing changes the metabolite mix in both directions. That can raise exposure to one compound while lowering it for another. The interaction is real in principle, poorly quantified in people, and belongs in formulation review rather than in a benefit claim.

Resveratrol and proanthocyanidin-rich grape seed extract co-occur in grape-derived material and are routinely formulated together, though the classes are chemically distinct and are absorbed and metabolised differently. Co-formulation is common practice with a compositional rationale. It is not evidence that the two act on the same target. Any joint effect would need its own study.

Berberine lowers fasting glucose in human trials and activates AMPK; resveratrol also activates AMPK and has reported effects on glycaemic markers. Stacking two ingredients that both push glucose in the same direction is an additive effect to flag, especially for anyone using glucose-lowering medication. The flag is the useful output here, not a promise of a bigger benefit. Neither the size nor the reliability of a combined effect is established.

Cinnamon trials on fasting glucose are mixed and heterogeneous in cultivar, dose and preparation. Where an effect is present it points the same direction as resveratrol's, so the combination is worth noting for anyone monitoring blood sugar. Confidence stays at Early because the cinnamon side is inconsistent. This is a flag rather than a recommendation.

Chromium is presented in supplement formulas as an insulin-signalling cofactor, and the human evidence for supplemental chromium at ordinary intakes is weak and inconsistent. In a formula it sits alongside resveratrol as a second ingredient aimed at the same markers. Anyone tracking blood sugar should know both are in the product. The confidence label reflects the weakness of the chromium side, not the strength of the pairing.

Gymnema is used in formulas aimed at glucose handling, with a human evidence base that is small and variable in extract standardisation. Combined with resveratrol the direction of effect on glucose markers is the same. That makes the pairing an additive-effect flag for anyone on glucose-lowering therapy. It is not a claim that the two work better together.

The two reach nitric oxide by different routes, one enzymatic through eNOS and one through nitrate reduction by oral bacteria. Both have been reported to lower blood pressure modestly in human trials, so the effects can add. That is worth flagging for anyone taking antihypertensive medication. The additive size in people is not quantified.

Citrulline raises plasma arginine more reliably than arginine itself does, which supplies more substrate to nitric oxide synthase, and resveratrol is reported to act on the enzyme side of the same step. Substrate plus enzyme activity is a coherent pairing on biochemistry. Both are also associated with small blood pressure reductions, which makes the combination one to flag rather than stack blindly. No combination trial is being cited.

Arginine is the direct substrate for nitric oxide synthase, and resveratrol has been reported to increase eNOS expression and activity in vascular cells. Pairing substrate with enzyme upregulation is mechanistically sensible. Oral arginine is heavily metabolised by intestinal arginase, which limits how much reaches the circulation. The blood pressure directions add, so flag it.

Resveratrol inhibits platelet aggregation in laboratory work and at high concentrations, and nattokinase has fibrinolytic activity of its own. Two ingredients touching haemostasis in one formula is a combination to flag, particularly with anticoagulant or antiplatelet medication. It is not a selling point. The human magnitude for the resveratrol side is not established.

Ginkgolide B antagonises platelet-activating factor, which is why ginkgo carries a standing bleeding-risk caution around surgery and anticoagulants. Resveratrol has its own reported platelet-inhibiting activity. The two together should be reviewed rather than assumed to be additive in benefit. Flagging the combination is the useful output.

Garlic's organosulfur compounds inhibit platelet aggregation in human studies, and resveratrol points the same way in laboratory work. Both also carry modest blood pressure effects. A formula holding both should note the additive direction, and anyone on antithrombotic medication should raise it with a clinician. Nothing here promises a larger benefit from the pair.

Polyphenol hydroxyl groups bind copper and iron, which is part of why polyphenols behave as antioxidants in some conditions and pro-oxidants in others. Taking a large stilbene dose alongside a trace mineral in the same capsule is worth checking for binding. What is established is the chemistry of the interaction, not a demonstrated reduction in copper status in people. Separating the doses is the ordinary formulation response.

Resveratrol acts largely by increasing transcription of antioxidant enzymes through Nrf2, and several of those enzymes are selenoproteins that need selenocysteine to function. Enzyme expression without the cofactor is not much use. That makes selenium adequacy part of the mechanism rather than a bonus. The connection is biochemical, and no combination trial is cited.

Lipoate and dihydrolipoate cycle in both water and lipid environments and can regenerate other antioxidants. Resveratrol works mostly upstream, on the transcription of antioxidant enzymes. Combining a direct redox cycler with a transcriptional one is coherent on paper. It remains a mechanism statement without a human combination outcome behind it.

Spermidine and resveratrol have both been reported to induce autophagy in cell and animal work, reaching it by different routes, spermidine largely by inhibiting acetyltransferase activity. Autophagic flux is a cellular marker, not an outcome anyone experiences. The human data for either compound on that endpoint are thin. Confidence sits at Early for exactly that reason.

Melatonin scavenges radicals and influences mitochondrial redox in cell and animal work, and it is often co-studied with polyphenols there. Any overlap with resveratrol lives in that preclinical literature. Melatonin also has its own sleep-timing pharmacology which is unrelated to this pairing. Early is the honest label.

Astaxanthin partitions across the lipid bilayer and quenches singlet oxygen there, while resveratrol works mainly through transcriptional upregulation of antioxidant enzymes. Different compartments and different mechanisms is the argument for combining them. It is a plausible complement, not a measured one. Confidence stays at Early.